[8-K] PLIANT THERAPEUTICS, INC. Reports Material Event

Rhea-AI Filing Summary

Pliant Therapeutics filed an 8‑K announcing it furnished a press release with financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1. The company states the information in this report, including the exhibit, is furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act. The report was signed by Keith Cummings, M.D., MBA, Chief Financial Officer.

0001746473FALSE00017464732025-11-062025-11-060001746473plrx:CommonStockParValue0.0001PerShareMember2025-11-062025-11-060001746473plrx:SeriesAJuniorParticipatingPreferredPurchaseRightsMember2025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________

FORM 8-K

__________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

__________________________________________

PLIANT THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

__________________________________________

Delaware			001-39303			47-4272481
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
331 Oyster Point Blvd., South San Francisco, CA						94080
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 481-6770

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

__________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.0001 per share			PLRX			The Nasdaq Stock Market LLC
Series A Junior Participating Preferred Purchase Rights			N/A			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02    Results of Operations and Financial Condition.

On November 6, 2025, Pliant Therapeutics, Inc. (the "Company") issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this report.

The information in this Current Report on Form 8-K including the exhibits furnished herewith shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the "Exchange Act") or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01     Financial Statements and Exhibits.

(d) Exhibits. 

Exhibit No.						Description
99.1						Press Release issued by the Company dated November 6, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			PLIANT THERAPEUTICS, INC.
Date: November 6, 2025			By:			/s/ Keith Cummings
						Keith Cummings, M.D., MBA
						Chief Financial Officer

FAQ

What did PLRX announce in this 8-K?

Pliant Therapeutics furnished a press release with financial results for the third quarter ended September 30, 2025.

Which period do the results cover for PLRX?

The results cover the third quarter ended September 30, 2025.

How were the results provided by PLRX?

They were provided via a press release furnished as Exhibit 99.1 to the 8‑K.

Is the information considered 'filed' under the Exchange Act?

No. The company states the information, including the exhibit, is furnished and not deemed “filed” under Section 18 of the Exchange Act.

Who signed the PLRX report?

The report was signed by Keith Cummings, M.D., MBA, Chief Financial Officer.

What is PLRX’s trading symbol and exchange?

The common stock trades under PLRX on The Nasdaq Stock Market LLC.